News headlines about Cynosure (NASDAQ:CYNO) have trended very positive this week, according to Alpha One Sentiment. The research firm, a subsidiary of Accern, identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cynosure earned a news impact score of 0.56 on Alpha One’s scale. Alpha One also assigned media headlines about the medical equipment provider an impact score of 25 out of 100, meaning that recent media coverage is very unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Alpha One Sentiment Analysis’s analysis:
- North America Scar Treatment Market Predicted to Rake US $4,190.6 Mn by 2022 (sbwire.com)
- Hologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure … (prnewswire.com)
- Global Laser Assisted Liposuction Devices Market 2017 : Cynosure Inc, Sciton Inc, Wells Johnson Co, Invasix Ltd (openpr.com)
- Asia-Pacific Anti-Aging Market is expected to reach $62.64 billion by 2021 (reports.pr-inside.com)
- Dermatology Devices Market Estimated to be Valued at US$ 5,307.6 Mn by 2026 (medgadget.com)
Shares of Cynosure (NASDAQ:CYNO) opened at 66.00 on Friday. The firm’s 50-day moving average price is $62.47 and its 200-day moving average price is $50.89. Cynosure has a 52-week low of $39.90 and a 52-week high of $66.65.
CYNO has been the topic of a number of research analyst reports. Northland Securities reiterated an “outperform” rating and set a $60.00 target price on shares of Cynosure in a research report on Thursday, February 16th. Aegis downgraded Cynosure from a “buy” rating to a “hold” rating in a research report on Wednesday, March 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. Cynosure presently has a consensus rating of “Hold” and an average target price of $58.63.
Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/cynosure-cyno-earning-very-favorable-press-coverage-study-shows/1914498.html
Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.